Bank of New York Mellon Corp boosted its stake in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 38.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,853 shares of the specialty pharmaceutical company’s stock after buying an additional 151,849 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.46% of Foamix Pharmaceuticals worth $2,528,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in FOMX. UBS Oconnor LLC acquired a new stake in Foamix Pharmaceuticals in the 1st quarter valued at $148,000. Renaissance Technologies LLC acquired a new stake in Foamix Pharmaceuticals in the 1st quarter valued at $307,000. Goldman Sachs Group Inc. boosted its stake in Foamix Pharmaceuticals by 363.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 148,981 shares of the specialty pharmaceutical company’s stock valued at $737,000 after buying an additional 116,861 shares in the last quarter. Marshall Wace North America L.P. acquired a new stake in Foamix Pharmaceuticals in the 1st quarter valued at $2,217,000. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in Foamix Pharmaceuticals in the 1st quarter valued at $2,217,000. 57.60% of the stock is currently owned by institutional investors and hedge funds.
Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) opened at 6.795 on Friday. The company has a 50-day moving average price of $5.50 and a 200 day moving average price of $4.90. Foamix Pharmaceuticals Ltd. has a 52 week low of $4.03 and a 52 week high of $11.27. The firm’s market cap is $254.31 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.05). The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $1.50 million. Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. Foamix Pharmaceuticals’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.27) EPS. Analysts expect that Foamix Pharmaceuticals Ltd. will post ($1.53) EPS for the current fiscal year.
WARNING: “Foamix Pharmaceuticals Ltd. (FOMX) Position Increased by Bank of New York Mellon Corp” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/10/13/foamix-pharmaceuticals-ltd-fomx-position-increased-by-bank-of-new-york-mellon-corp.html.
FOMX has been the topic of several recent analyst reports. Credit Suisse Group reaffirmed a “buy” rating and issued a $9.00 price target on shares of Foamix Pharmaceuticals in a research note on Wednesday, July 19th. HC Wainwright initiated coverage on Foamix Pharmaceuticals in a research note on Thursday, August 24th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Zacks Investment Research lowered Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
Want to see what other hedge funds are holding FOMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX).
Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.